

شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلو

بسم الله الرحمن الرحيم





HANAA ALY



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكرونيله



شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم



HANAA ALY



شبكة المعلومات الجامعية التوثيق الإلكترونى والميكروفيلم

جامعة عين شمس التوثيق الإلكتروني والميكروفيلم قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها على هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



HANAA ALY



Left Ventricular Function in Recovered COVID 19 Patients using 4 Dimension Echocardiography and Conventional Echocardiography

Thesis

Submitted for Partial Fulfillment of Master Degree in **Cardiology**

By

Aly Osama Abdelhady Elsayed
M.B., B.Ch, Ain Shams University

Under Supervision of

Prof. Dr. Walaa Adel

Professor of Cardiology Faculty of Medicine, Ain Shams University

Dr. Viola William

Assistant Consultant of Cardiology Faculty of Medicine, Ain Shams University

Dr. Hazem Mansour

Lecturer of Cardiology Faculty of Medicine, Ain Shams University

Faculty of Medicine, Ain Shams University
2021



سورة البقرة الآية: ٣٢

Acknowledgments

First and foremost, I feel always indebted to **Allah** the Most Beneficent and Merciful.

I wish to express my deepest thanks, gratitude and appreciation to **Prof. Dr. Walaa Adel**, Professor of Cardiology, Faculty of Medicine, Ain Shams University, for her meticulous supervision, kind guidance, valuable instructions and generous help.

Special thanks are due to **Dr. Viola William**, Assistant Consultant of Cardiology, Faculty of Medicine, Ain Shams University, for her sincere efforts, fruitful encouragement.

I am deeply thankful to **Dr. Hazem Mansour**, Lecturer of Cardiology, Faculty of Medicine, Ain Shams University, for his great help, outstanding support, active participation and guidance.

I would like to express my hearty thanks to all my family for their support till this work was completed.

Aly Osama Abdelhady Elsayed

Tist of Contents

Title	Page No.
List of Tables	i
List of Figures	ii
Introduction	1
Aim of the Work	4
Review of Literature	
Coronavirus Disease 2019 (COVID-19)	5
Real-Time Three-Dimensional Echocardiography.	17
Patients and Methods	34
Results	50
Discussion	65
Limitations	71
Conclusion	72
Summary	73
References	
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Table 1:	Showing grading of LV diastolic functi	ion 41
Table 2:	Demographic data:	51
Table 3:	Risk Factors:	52
Table 4:	Laboratory finding:	54
Table 5:	2D Echocardiography findings:	55
Table 6:	2D Echocardiography findings (cont)) 56
Table 7:	2D Echocardiography findings (cont)) 57
Table 8:	2D Echocardiography findings (cont))58
Table 9:	Global longitudinal strain of LV:	59
Table 10:	4D echocardiography of Left ventricle:	60
Table 11:	Shows the relation between those Normal GLS versus who had Abnorregarding demographic data	mal GLS
Table 12:	Shows the relation between those Normal GLS versus who had Abnorregarding Risk factors:	mal GLS
Table 13:	Shows the relation between those Normal GLS versus who had Abnorregarding laboratory findings:	mal GLS

Tist of Figures

Fig. No.	Title	Page No.
Figure 1:	Risk factors in patients infected with 19·	
Figure 2:	COVID-19 and heart failure	
Figure 3:	Modes of 3D echocardiography	20
Figure 4:	Proper alignment of the two long	
8	planes of the left ventricle as indicate red and green lines	ed by the24
Figure 5:	The top two quadrants show the mark points-medial mitral annuli, latera	
	annulus, apex (in the first qu	
	anterior and inferior mitral annulus	
T	second quadrant)	
Figure 6:	End systolic frame with end-systolic	•
	stroke volume, and ejection	
Figure 7:	calculated by 3D Endocardial and epicardial borde	
rigure 7.	traced in the end-diastolic frame in the	
	2 chamber views (upper left and right	
Figure 8:	Parametric image display of se	
118411001	timing (above) and excursion (belo	•
	patient with dilated cardiomyopathy.	
Figure 9:	LA volume measurement in apic	
	chamber view.(From our work	Patient
	Number 22)	38
Figure 10:	Assessment of diastolic function using	•
	across the mitral valve .(From or	
_	Patient Number 9)	
Figure 11:	Measurement of tricuspid annula	
	systolic excursion (TAPSE).(From o	
	patient Number 2)	42

Tist of Figures cont...

Fig. No.	Title	Page No.
Figure 12:	Tissue Doppler imaging at the annulus, showing peak long excursion velocity of the basal RV (S').(from our work patient number 1-	gitudinal free wall
Figure 13:	Illustrations of the Steps involved in tracking echocardiography	-
Figure 14:	Stepwise guide for LV analysis	48
Figure 15:	Assessment of LV volumes	By 4D
	echocardiography (from our work	patient
	Number 22)	49
Figure 16:	Demographic data	51
Figure 17:	Risk factors analysis as regard smoki	ng 53
Figure 18:	Risk factors analysis as regard hype	ertension
	and diabetes	53
Figure 19:	Shows the relation between those	who had
_	Normal GLS versus who had Abnor	mal GLS
	regarding demographic data	62
Figure 20:	Relation between those who had Nor	mal GLS
_	versus who had Abnormal GLS r	egarding
	demographic data	62
Figure 21:	Shows the relation between those	who had
-	Normal GLS versus who had Abnor	
	regarding Risk factors:	63

Tist of Abbreviations

Abb.	Full term
0.1	Thus dimension
	Two dimension
	Four dimension
	Angiotensin converting enzyme
	Body surface area
	Complete blood picture
	Cardio vascular disease
	End diastolic dimensions
	End diastolic volume
	End systolic dimensions
	End systolic volume
	Fractional area change
	Global longitudinal strain
	Heart failure
<i>HGB</i>	Hemoglobin
<i>IL6</i>	Interleukin 6
<i>LAV</i>	Left atrium volume
<i>LV</i>	Left ventricle
LVEF	Left ventricle ejection fraction
<i>MCP</i>	Monocyte chemoattractant protein
<i>PLT</i>	
<i>PWD</i>	Pulse wave Doppler
<i>RAAS</i>	Renin angiotensin aldosterone system
RT3D	Real time three dimensional
<i>TAPSE</i>	Tricuspid annular plane systolic excursion
	Tissue Doppler imaging
	Total leucocytic count
	Tumor necrosing factor
	Tricuspid regurgitation
	10 0

Introduction

Corona virus diseases (COVID 19) is defined an illness caused by a novel corona virus called severe acute respiratory distress syndrome corona virus 2 (SARS COV 2) it was first identified as outbreak as respiratory illness in Wuhan City and later on March 11,2020 and later it was declared as global pandemic.

Presentations of COVID -19 ranged from asymptomatic mild cases up to sever cases which leads finally to death.

Symptoms may develop from 2 days up to 2weeks after exposure. Fever is the most common symptom of COVID-19, other common symptoms include cough, loss of appetite, fatigue, shortness of breath, sputum production, fatigue, diarrhea. Less common symptoms include runny nose, sore throat, skin lesions.

There are several testing protocols for the disease, The standard method is real time reverse transcription polymerase chain reaction (rRT-PCR) . Also Chest CT scans may be done.

The impact of COVID 19 on the Heart is largely unknown but it is at higher risk of failure. Increased afterload from pulmonary embolism, negative inotropic effects of cytokines, and direct angiotensin converting enzyme 2mediated cardiac injury from COVID 19 are potential mechanisms that can affect the heart (1).

But Right now Little is known about the cardiac manifestations of COVID-19 because all the data gathered until now were based on laboratory and clinical evaluation or case reports in deteriorating patients We need more follow-up research on the patients that recovered from their illness, to assess the short- and long-term clinical implications of cardiac disease in COVID-19 and to assess for the pathogenesis of RV dysfunction in this disease.

Evaluation of left ventricular size and function are the most common reasons for performing echocardiography in the adult patient. Important diagnostic, prognostic, and treatment decisions depends on LV morphology analysis; the widespread bedside availability, cost, and non-invasive nature echocardiography means that this technique has become the method of choice in most situations for performing this analysis. However, both M mode and two dimensional (2D) echocardiography make important geometric assumptions about the LV which leads to inaccuracies in measurements. Many echocardiographic departments perform "eyeball" analysis of global and regional LV function and provide visual estimates of ejection fraction because existing quantification methods (from M mode and 2D Echo) are both time consuming and difficult to perform. In an era when so many important and often costly decisions are made upon these data it is incumbent upon departments that accurate and reproducible echo quantification methods are utilised—especially since the "gold standard"



technique of cardiac magnetic resonance (CMR) is not so widely available, is more costly, cannot be used on those with implanted pacemakers or defibrillators, and is disliked by many patients.

Real Time Three dimensional (RT3D) echocardiography has been available for several years using time consuming and difficult reconstruction techniques (often utilizing transoesophageal studies). However, recent advances computer processing and transducer construction techniques have meant that real time transthoracic 3D echocardiography is now available from major ultrasound system manufacturers. Software programs to analyse 3D datasets of the LV are also now readily available; this combination of new instrumentation and software has been shown to provide highly accurate (compared to CMR) analysis of LV morphology and function, such that this methodology is likely to ensure that echocardiography remains the first choice technique for non-invasive evaluation of the LV.

AIM OF THE WORK

im of the Work is to study the effect of COVID 19 on Left Ventricular Function and dimensions using 4D Echocardiography in recovered patients.